2020-2034 Assessment Of The Neuro-Cells Market: Funding And Regulatory Progress Accelerate Development
Dublin, Sept. 10, 2026 (GLOBE NEWSWIRE) -- The "Neuro-Cells Sales Forecast, and Market Size Analysis - 2034" has been added to ResearchAndMarkets.com's offering.
The report provides a comprehensive assessment of the investigational cell therapy's clinical development, regulatory progress, competitive positioning and commercial potential across the seven major markets. These markets include the United States, Germany, France, Italy, Spain, the United Kingdom and Japan.
Developed by Neuroplast, Neuro-Cells is an autologous bone marrow-derived hematopoietic and mesenchymal stem cell therapy under investigation for acute traumatic spinal cord injury (TSCI). The therapy is administered intrathecally during the acute phase following injury and is designed to reduce secondary inflammatory damage, preserve neurological function and support functional recovery.
Key Factors Driving the Neuro-Cells Market
- Significant unmet need in traumatic spinal cord injury: No regenerative pharmacotherapy is currently approved for acute TSCI in Europe or the United States. Neuroplast estimates that approximately 29,000 people sustain acute TSCI annually across these regions, with an associated socioeconomic burden exceeding €11.4 billion, or approximately US$13 billion, per year. A therapy capable of delivering clinically meaningful neurological recovery could address a substantial treatment gap. Favorable clinical safety profile: In a completed Phase I study involving 10 patients with TSCI, Neuro-Cells demonstrated favorable safety and tolerability, with no product-related serious adverse events reported. These results supported continued clinical development through a randomized, placebo-controlled program. Progress in later-stage development: Neuroplast completed enrollment of 16 patients in a multicenter Phase II study in September 2023. The company also secured authorization from Spanish and Danish regulators for a combined Phase II/III study, supporting an accelerated clinical and regulatory strategy. Potential expansion into additional neurological indications: Neuroplast is evaluating the broader potential of Neuro-Cells in amyotrophic lateral sclerosis, frontotemporal dementia, Alzheimer's disease, Parkinson's disease and traumatic brain injury. Successful clinical validation in TSCI could support further development using the company's existing manufacturing platform. Financial support for development: Neuroplast raised €10 million, approximately US$11.5 million, through Series B financing to advance clinical development and pursue conditional European Medicines Agency approval.
Recent Neuro-Cells Clinical Development
In November 2021, Neuroplast and Hospital Nacional de Paraplejicos de Toledo in Spain announced positive Phase I results following the evaluation of 10 patients with traumatic spinal cord injury. The findings indicated that Neuro-Cells was safe and well tolerated, with no product-related adverse events reported. The study provided an important clinical foundation for subsequent randomized development.
Neuro-Cells has also received orphan drug designation from the U.S. Food and Drug Administration and the European Commission for traumatic spinal cord injury. These designations reinforce the therapy's potential relevance in a serious condition with limited restorative treatment options.
Neuro-Cells Sales Forecast and Market Outlook
Neuroplast has not published official revenue guidance for Neuro-Cells, and verified analyst consensus estimates are not available through company filings or regulatory sources. Specific sales projections should therefore be interpreted in the context of clinical, regulatory, pricing and reimbursement uncertainty.
If ongoing studies confirm efficacy and support regulatory approval, Neuro-Cells could secure an early market position in regenerative medicine for acute TSCI. Its long-term commercial potential may also benefit from geographic expansion and successful development in additional neurodegenerative and neurological conditions.
The Neuro-Cells market report evaluates historical performance, anticipated market entry, forecast sales through 2034 and potential uptake across target indications. It also examines pricing strategies, reimbursement conditions, regional cost variations and factors that may influence adoption in the United States, Europe and Japan.
Scope of the Neuro-Cells Market Report
- Detailed product analysis covering mechanism of action, dosage, administration and clinical development. Assessment of Neuro-Cells in spinal cord injury, amyotrophic lateral sclerosis, frontotemporal dementia and traumatic brain injury. Review of clinical trials, including interventions, study status, enrollment, timelines and completion dates. Analysis of regulatory milestones, orphan designations and anticipated commercialization pathways. Current and forecast Neuro-Cells sales analysis through 2034 across the seven major markets. Evaluation of market size, peak sales potential, pricing strategy and reimbursement outlook. Patent assessment, potential generic or biosimilar entry considerations and possible pricing impact. Competitive intelligence covering marketed treatments, pipeline therapies and anticipated launch timelines. SWOT analysis supported by analyst perspectives on clinical and commercial positioning. Review of partnerships, licensing transactions, mergers, acquisitions and other strategic activity.
Competitive and Clinical Assessment
The report analyzes the competitive landscape for Neuro-Cells across its target indications, including the number and development status of competing therapies. It evaluates potential clinical differentiation based on safety, efficacy, administration, manufacturing requirements and market positioning.
Emerging therapies for spinal cord injury, amyotrophic lateral sclerosis, frontotemporal dementia and traumatic brain injury may affect future market share and adoption. The report assesses these competitive risks alongside the potential advantages of Neuro-Cells, including its autologous platform, clinical safety findings and development strategy.
Strategic Value of the Report
The report is designed to support pharmaceutical companies, biotechnology organizations, investors, healthcare stakeholders and portfolio strategy teams. Its analysis of the Neuro-Cells market forecast through 2034 provides insight into clinical milestones, commercialization scenarios, competitive threats, pricing considerations and potential revenue opportunities across major global markets.
By combining clinical, regulatory and commercial intelligence, the report offers a structured view of the opportunities and risks that may shape the future of Neuro-Cells in traumatic spinal cord injury and other neurological indications.
Key Topics Covered
1. Report Introduction
2. Neuro-cells Overview in potential indication like Spinal cord injuries, Amyotrophic lateral sclerosis, Frontotemporal dementia, and Traumatic brain injuries
2.1. Product Detail
2.2. Neuro-cells Clinical Development
2.2.1. Neuro-cells Clinical studies
2.2.2. Neuro-cells Clinical trials information
2.2.3. Safety and efficacy
2.3. Other Developmental Activities
2.4. Product Profile
3. Neuro-cells Competitive Landscape (Marketed Therapies)
4. Competitive Landscape (Late-stage Emerging Neuro-cells Therapies)
5. Neuro-cells Market Assessment
5.1. Neuro-cells Market Outlook in potential indications
5.2. 7MM Analysis
5.2.1. Neuro-cells Market Size in the 7MM for potential indications
5.3. Country-wise Market Analysis
5.3.1. Neuro-cells Market Size in the United States for potential indications
5.3.2. Neuro-cells Market Size in Germany for potential indications
5.3.3. Neuro-cells Market Size in France for potential indications
5.3.4. Neuro-cells Market Size in Italy for potential indications
5.3.5. Neuro-cells Market Size in Spain for potential indications
5.3.6. Neuro-cells Market Size in the United Kingdom for potential indications
5.3.7. Neuro-cells Market Size in Japan for potential indications
6. Neuro-cells SWOT Analysis
7. Analysts' Views
8. Appendix
8.1. Bibliography
8.2. Report Methodology
List of Tables
Table 1: Neuro-cells, Clinical Trial Description, 2023
Table 2: Neuro-cells, General Description
Table 3: Competitive Landscape (Marketed Therapies)
Table 4: Competitive Landscape (Emerging Therapies)
Table 5: Neuro-cells's pricing and cost Assumptions
Table 6: Neuro-cells's Sales Analysis in the 7MM, in USD million (2020-2034)
Table 7: Neuro-cells Market Size in the US, in USD million (2020-2034)
Table 8: Neuro-cells Market Size in Germany, in USD million (2020-2034)
Table 9: Neuro-cells Market Size in France, in USD million (2020-2034)
Table 10: Neuro-cells Market Size in Italy, in USD million (2020-2034)
Table 11: Neuro-cells Market Size in Spain, in USD million (2020-2034)
Table 12: Neuro-cells Market Size in the UK, in USD million (2020-2034)
Table 13: Neuro-cells Market Size in Japan, in USD million (2020-2034)
List of Figures
Figure 1: Neuro-cells's Sales Analysis in the 7MM, USD million (2020-2034)
Figure 2: Neuro-cells Market Size in the United States, USD million (2020-2034)
Figure 3: Neuro-cells Market Size in Germany, USD million (2020-2034)
Figure 4: Neuro-cells Market Size in France, USD million (2020-2034)
Figure 5: Neuro-cells Market Size in Italy, USD million (2020-2034)
Figure 6: Neuro-cells Market Size in Spain, USD million (2020-2034)
Figure 7: Neuro-cells Market Size in the United Kingdom, USD million (2020-2034)
Figure 8: Neuro-cells Market Size in Japan, USD million (2020-2034)
For more information about this report visit
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.
Comments
No comment